HealthJ&J eyes US filing for Caplyta in bipolar mania after second trial win
Johnson & Johnson said its drug Caplyta outperformed placebo in easing manic symptoms in a second late-stage study of people with bipolar I disorder, setting the stage for a planned US regulatory filing.
J&J eyes US filing for Caplyta in bipolar mania after second trial win
